Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.82)
# 485
Out of 5,043 analysts
405
Total ratings
50.8%
Success rate
17.3%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Reiterated: Buy | $40 | $8.34 | +379.62% | 13 | Sep 28, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $42 | $8.07 | +420.45% | 27 | Sep 25, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $35.53 | $10.63 | +234.21% | 5 | Sep 24, 2026 | |
| IVA Inventiva | Reiterated: Buy | $15 | $3.16 | +374.68% | 20 | Sep 23, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | n/a | $301.81 | - | 10 | Sep 22, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $95 | $28.51 | +233.22% | 26 | Sep 22, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $56 → $70 | $53.24 | +31.48% | 11 | Aug 11, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $90 | $25.54 | +252.39% | 9 | Aug 7, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $30 | $13.19 | +127.45% | 25 | Aug 7, 2026 | |
| EOLS Evolus | Reiterated: Buy | $17 | $7.73 | +119.92% | 27 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $230 → $275 | $218.42 | +25.90% | 42 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $3.40 | +1,076.47% | 1 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $138.77 | +80.15% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $23.37 | +122.51% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $55 | $42.67 | +28.90% | 31 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $7.25 | +286.21% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.61 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.799 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2,468.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.03 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $6.11 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21.38 → $19.96 | $8.64 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.0079 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $1.89 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $2.06 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $15.06 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $7.89 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $121.19 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $13.74 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $32.55 | n/a | 1 | Oct 18, 2011 |
Oculis Holding AG
Sep 28, 2026
Reiterated: Buy
Price Target: $40
Current: $8.34
Upside: +379.62%
REGENXBIO
Sep 25, 2026
Reiterated: Buy
Price Target: $42
Current: $8.07
Upside: +420.45%
Eupraxia Pharmaceuticals Inc.
Sep 24, 2026
Reiterated: Buy
Price Target: $35.53
Current: $10.63
Upside: +234.21%
Inventiva
Sep 23, 2026
Reiterated: Buy
Price Target: $15
Current: $3.16
Upside: +374.68%
Ligand Pharmaceuticals
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $301.81
Upside: -
Viking Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $95
Current: $28.51
Upside: +233.22%
MBX Biosciences
Aug 11, 2026
Reiterated: Buy
Price Target: $56 → $70
Current: $53.24
Upside: +31.48%
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $90
Current: $25.54
Upside: +252.39%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $13.19
Upside: +127.45%
Evolus
Aug 6, 2026
Reiterated: Buy
Price Target: $17
Current: $7.73
Upside: +119.92%
Aug 4, 2026
Reiterated: Buy
Price Target: $230 → $275
Current: $218.42
Upside: +25.90%
Jul 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $3.40
Upside: +1,076.47%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $138.77
Upside: +80.15%
May 7, 2026
Reiterated: Buy
Price Target: $52
Current: $23.37
Upside: +122.51%
May 6, 2026
Reiterated: Hold
Price Target: $55
Current: $42.67
Upside: +28.90%
Jan 15, 2026
Reiterated: Buy
Price Target: $28
Current: $7.25
Upside: +286.21%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.61
Upside: -
Apr 1, 2025
Reiterated: Buy
Price Target: $8
Current: $0.799
Upside: n/a
Jan 8, 2025
Reiterated: Buy
Price Target: n/a
Current: $2,468.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.03
Upside: n/a
Aug 30, 2023
Reiterated: Hold
Price Target: $11
Current: $6.11
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $21.38 → $19.96
Current: $8.64
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.0079
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $1.89
Upside: n/a
May 6, 2021
Reiterated: Buy
Price Target: $6 → $5
Current: $2.06
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $15.06
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $7.89
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $121.19
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $13.74
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $32.55
Upside: n/a